<DOC>
	<DOCNO>NCT00004878</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill cancer cell . Sometimes transplanted cell reject body 's normal tissue . Donor lymphocytes treated laboratory may prevent happen . PURPOSE : Randomized phase II trial study effectiveness donor lymphocytes prevent graft-versus-host disease patient undergoing peripheral stem cell transplantation chronic myeloid leukemia .</brief_summary>
	<brief_title>Donor Lymphocytes Prevent Graft-Versus-Host Disease Patients With Chronic Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare incidence acute graft versus host disease ( GVHD ) grade II-IV extensive chronic GVHD chronic myeloid leukemia patient treat purged donor lymphocyte infusion ( DLI ) process CD8 high density microparticles ( HDM ) v unpurged DLI follow nonmyeloablative , HLA identical sibling peripheral blood stem cell transplantation . II . Compare rate complete cytogenetic , clinical , hematologic remission mortality GVHD patient treat regimen . III . Determine efficacy CD8 HDM deplete great 95 % CD8+ cell donor lymphocyte . IV . Compare safety toxicity regimens patient . OUTLINE : This randomize , double blind , multicenter study . Patients stratified age ( 60 vs 60 ) center . Allogeneic peripheral blood stem cell ( PBSC ) harvest select CD34+ cell day 5-8 . Nonmyeloablative conditioning : Patients receive fludarabine IV 30 minute cytarabine IV 4 hour ( begin 4 hour start fludarabine infusion ) day -6 -3 idarubicin IV 1-5 minute day -6 -4 . Filgrastim ( G-CSF ) administer subcutaneously daily begin day -2 continue blood count recover . Graft versus host disease prevention : Beginning day -2 , patient receive tacrolimus IV continuously oral dosing tolerate . Patients receive tacrolimus combination methotrexate day 1 , 3 , 6 completion transplantation . Beginning 12 week completion transplantation , oral tacrolimus taper stop 4 week . Transplantation : Allogeneic PBSC infuse day 0 . At 4 month posttransplantation , patient residual Ph+ cell cytogenetics FISH OR hematologic clinical evidence chronic myeloid leukemia AND without symptomatic chronic graft versus host disease require immunosuppressive therapy randomize 1 2 treatment arm : Arm I : Lymphocytes harvest original PBSC donor process CD8 high density microparticle device remove CD8+ cell . Patients receive CD8+ cell deplete donor lymphocyte infusion ( DLI ) IV 15-30 minute day collection . Arm II : Lymphocytes harvest original PBSC donor . Patients receive undepleted DLI IV 15-30 minute day collection . Patients follow day 30 , 60 , 100 , 180 , periodically year 5 . PROJECTED ACCRUAL : A maximum 110 patient ( 55 per arm ) accrue study within 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove chronic myeloid leukemia ( CML ) first chronic phase cytogenetic hematologic evidence acceleration ( clonal evolution ) Availability 6 antigen ( A , B , DR locus ) HLA identical sibling donor Eligible randomization donor lymphocyte infusion ( DLI ) : Residual Ph+ cell cytogenetics FISH hematologic clinical evidence CML AND No graft versus host disease require immunosuppressive therapy within past 2 week AND Evidence donor hematopoiesis completion transplantation Ineligible randomization DLI : Blast transformation CML OR Prior interferon alfa relapse completion transplantation PATIENT CHARACTERISTICS : Age : 50 70 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 3 mg/dL Renal : Creatinine le 2 mg/dL Cardiovascular : Cardiac ejection fraction great 40 % Pulmonary : DLCO great 45 % predict Other : No active infection Not pregnant Negative pregnancy test No hypersensitivity nickel No hypersensitivity mouse proteins Human antimouse antibody positivity allow allergic history HIV negative HTLV antibody negative PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent hematopoietic growth factor filgrastim ( GCSF ) No biologic therapy ( e.g. , interferon alfa ) 6 month completion study therapy Chemotherapy : No chemotherapy 6 month completion study therapy Concurrent hydroxyurea allow CML relapse Endocrine therapy : Concurrent methylprednisolone allow grade II bad GVHD develop Radiotherapy : No radiotherapy 6 month completion study therapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>graft versus host disease</keyword>
</DOC>